Selected article for: "acute sars respiratory syndrome and adjuvant vaccine"

Author: Gupta, Tania; Gupta, Shishir K
Title: Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
  • Cord-id: npc9qdex
  • Document date: 2020_6_18
  • ID: npc9qdex
    Snippet: The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Furthe
    Document: The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This not only decreases the cost of a vaccine and make it affordable, but also reduces the quantity of the antigen used. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emerging SARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease.

    Search related documents:
    Co phrase search for related documents
    • access gain and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • acquired immunodeficiency and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acquired immunodeficiency and acute respiratory distress syndrome: 1, 2, 3, 4
    • acquired immunodeficiency and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acquired immunodeficiency and adaptive innate: 1, 2
    • acquired immunodeficiency syndrome aids and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acquired immunodeficiency syndrome aids and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • acquired immunodeficiency syndrome and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acquired immunodeficiency syndrome and acute respiratory distress syndrome: 1, 2, 3
    • acquired immunodeficiency syndrome and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7
    • action mode and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mode and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6
    • action mode and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mode and adaptive innate: 1, 2, 3, 4, 5, 6, 7
    • action mode and adaptive innate immune system: 1
    • action mode and adjuvant action: 1, 2
    • acute respiratory and ade induce: 1, 2
    • acute respiratory and ade trigger: 1, 2, 3
    • acute respiratory and adjuvant action: 1